News
Lab updates
Snapshots from conferences, collaborations, and study milestones.
Riaz Lab publishes on intratumoral bacteria and ICB + RT response
New Nat Cancer study links intratumoral microbiome and tumor ecosystem features with response and resistance to immune checkpoint blockade plus chemoradiotherapy in head and neck cancer.
ASTROnews Winter 2025 feature on H&N biomarkers
ASTROnews publishes “Winter Is Coming: The Changing Landscape of Head & Neck Cancer Biomarkers” by N. Riaz & B. Chera—a reader-friendly overview of precision biomarkers.
Media pickup: Bioengineer.org recaps ASTRO lymphocyte-sparing study
Bioengineer.org spotlights our analysis linking lymphocyte preservation to better outcomes—supporting dose and volume de-escalation for HPV-positive disease.
Phase III trial 24-200 (NCT06563479) opens with Riaz as co-investigator
MSK launches a personalized 3-week chemoradiation protocol (FMISO-selected) versus standard 7-week CRT for HPV-positive OPC, listing Dr. Riaz as co-investigator.
Shu Yazaki publishes AlphaMissense DDR study
Postdoctoral fellow Shu Yazaki reports in JCO Precision Oncology on using AlphaMissense to classify DDR-associated mutations across cancer cohorts.
Phase II trial 25-040 (NCT06984861) launches
MSK opens trial 25-040: reduced-dose (30 Gy/3 weeks) CRT with adaptive escalation based on early response, listing Dr. Riaz as co-investigator.